Market News

Global Drug Abuse Treatment Market- Recent Developments

New Product Launches/Approvals:

In May 23, 2023, Braeburn Inc. a pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for BRIXADI (buprenorphine) extended-release injection for subcutaneous use, a new weekly and monthly medication for moderate to severe opioid use disorder.
In November 2022, Tempero Bio, Inc., a clinical-stage biopharmaceutical company received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for TMP-301. TMP-301 is the company's investigational metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) candidate used for treatment in cocaine use disorders (CUD).
On May 16, 2023, Perrigo Company plc. a pharmaceutical company received final approval from the U.S. Food and Drug Administration for nicotine coated mint lozenges, 2 mg and 4 mg over-the-counter (OTC). Nicotine polacrilex lozenges helps to reduce withdrawal symptoms in consumers who are trying to quit smoking.

Acquisition and Collaborations:

In January 2022, Pfizer Inc. a pharmaceutical company collaborated with Alex Therapeutics a digital therapeutics company to form a strategic commercial partnership to use Alex Therapeutics (artificial intelligence) AI-based platform for cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) for nicotine cessation in nicotine-addicted patients.

Drug Abuse Treatment Market Report Snapshots